Development of Diclofenac Sodium 3D Printed Cylindrical and Tubular-Shaped Tablets through Hot Melt Extrusion and Fused Deposition Modelling Techniques.

hot melt extrusion (HME) quality by design (QbD) release kinetics three-dimensional printing (3DP)

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
26 Jul 2023
Historique:
received: 23 06 2023
revised: 20 07 2023
accepted: 22 07 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

The present study aimed to develop 3D printed dosage forms, using custom-made filaments loaded with diclofenac sodium (DS). The printed tablets were developed by implementing a quality by design (QbD) approach. Filaments with adequate FDM 3D printing characteristics were produced via hot melt extrusion (HME). Their formulation included DS as active substance, polyvinyl alcohol (PVA) as a polymer, different types of plasticisers (mannitol, erythritol, isomalt, maltodextrin and PEG) and superdisintegrants (crospovidone and croscarmellose sodium). The physicochemical and mechanical properties of the extruded filaments were investigated through differential scanning calorimetry (DSC), X-ray diffraction (XRD) and tensile measurements. In addition, cylindrical-shaped and tubular-shaped 3D dosage forms were printed, and their dissolution behaviour was assessed via various drug release kinetic models. DSC and XRD results demonstrated the amorphous dispersion of DS into the polymeric filaments. Moreover, the 3D printed tablets, regardless of their composition, exhibited a DS release of nearly 90% after 45 min at pH 6.8, while their release behaviour was effectively described by the Korsmeyer-Peppas model. Notably, the novel tube design, which was anticipated to increase the drug release rate, proved the opposite based on the

Identifiants

pubmed: 37630976
pii: ph16081062
doi: 10.3390/ph16081062
pmc: PMC10459775
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Romanian UEFISCDI
ID : PN-III-P4-PCE-2021-1119

Références

Int J Pharm. 2015 Dec 30;496(2):414-20
pubmed: 26481468
Int J Pharm. 2020 Aug 30;586:119591
pubmed: 32640268
Molecules. 2021 May 22;26(11):
pubmed: 34067434
Int J Pharm. 2016 Feb 29;499(1-2):376-394
pubmed: 26757150
Mar Drugs. 2011;9(9):1649-1663
pubmed: 22131963
J Pharm Sci. 2009 Apr;98(4):1206-19
pubmed: 18752289
AAPS J. 2018 Sep 12;20(6):101
pubmed: 30209693
Int J Pharm. 2015 Oct 30;494(2):657-663
pubmed: 25934428
Int J Pharm. 2022 Feb 5;613:121411
pubmed: 34954001
Carbohydr Polym. 2017 Dec 1;177:49-57
pubmed: 28962795
Int J Pharm. 2017 Jul 15;527(1-2):21-30
pubmed: 28502898
ACS Omega. 2019 Mar 18;4(3):5412-5423
pubmed: 31459706
J Control Release. 2018 Jan 10;269:355-363
pubmed: 29146240
J Pharm Sci. 1963 Dec;52:1145-9
pubmed: 14088963
J Control Release. 1998 Feb 12;51(2-3):313-25
pubmed: 9685929
Curr Med Res Opin. 2010 Jul;26(7):1715-31
pubmed: 20470236
Int J Pharm. 2022 Mar 25;616:121553
pubmed: 35131354
Expert Opin Drug Deliv. 2016;13(3):451-64
pubmed: 26886062
Eur J Pharm Sci. 2021 Mar 1;158:105655
pubmed: 33253883
Int J Pharm. 2014 Jan 1;459(1-2):62-4
pubmed: 24239831
Int J Pharm. 2020 Apr 30;580:119200
pubmed: 32156531
Eur J Pharm Sci. 2015 Feb 20;68:11-7
pubmed: 25460545
J Pharm Sci. 1983 Oct;72(10):1189-91
pubmed: 6644570
Eur J Pharm Sci. 2019 Mar 1;129:110-123
pubmed: 30610954
Int J Pharm. 2020 Oct 15;588:119728
pubmed: 32768526
Eur J Pharm Sci. 2018 Jun 15;118:191-199
pubmed: 29559404
Int J Pharm. 2021 Sep 25;607:120922
pubmed: 34303815
J Pharm Pharmacol. 2015 May;67(5):673-84
pubmed: 25615235
Chem Pharm Bull (Tokyo). 2001 Oct;49(10):1245-50
pubmed: 11605648
Farmaco. 2005 Feb;60(2):171-7
pubmed: 15752476
Eur J Pharm Biopharm. 2015 Oct;96:380-7
pubmed: 26277660
Carbohydr Polym. 2015 May 20;122:152-9
pubmed: 25817654

Auteurs

Tryfon Digkas (T)

Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

Alina Porfire (A)

Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hațieganu", 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.

Jeroen Van Renterghem (J)

Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

Aseel Samaro (A)

Laboratory of Pharmaceutical Technology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

Gheorghe Borodi (G)

National Institute for Research and Development of Isotopic and Molecular Technologies, 65-103 Donath Street, 400293 Cluj-Napoca, Romania.

Chris Vervaet (C)

Laboratory of Pharmaceutical Technology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

Andrea Gabriela Crișan (AG)

Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hațieganu", 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.

Sonia Iurian (S)

Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hațieganu", 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.

Thomas De Beer (T)

Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

Ioan Tomuta (I)

Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Hațieganu", 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.

Classifications MeSH